Kestra Medical Technologies, Ltd. (KMTS)
NASDAQ • Healthcare
Last close at September 9, 2026 at 20:00 UTC
Metrics Over Time
Where the Money Goes
Q2 2026Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
Sep 14
in 4 daysQ3 2026% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
Kestra Medical Technologies’ preliminary fiscal fourth-quarter 2026 results topped consensus on revenue but trailed on EPS, as reported July 14, 2026. Revenue rose 66.2% to about $28.6 million (up from about $17.2 million a year ago), with the quarter’s scale showing up in gross profit of roughly $15.7 million and gross margin of about 55%. Operating costs continued to outweigh the revenue base, with operating income of around -$39.3 million and operating margin of about -137%. Net income was roughly -$38.8 million, improving 25.4% year over year from about -$52.1 million. On the tape, revenue of $28.6 million topped the $26.5 million estimate, +8%, while EPS of -$0.67 trailed the -$0.59 estimate by -$0.08. Cash flow remained negative, with negative operating cash flow of about $18.7 million, and the company paid roughly $0.3 million in dividends. Next-period consensus calls for EPS of -$0.62 on revenue of $29.0 million.
Next report — what to expect
Kestra Medical Technologies, Ltd. (KMTS) reports on September 14, 2026. Wall Street is looking for EPS of -$0.616 on revenue of $29.0 million. For trailing context, revenue grew +66.2% year over year last quarter. KMTS has beaten EPS in 1 of its 6 most recent quarters.
About Kestra Medical Technologies, Ltd.
Kestra Medical Technologies, Ltd. develops cardiac care devices and related services for the healthcare market, with a focus on wearable technologies and connected patient management. Listed on the NASDAQ as KMTS, the company generated $95.1 million in FY2026 revenue from medical instruments and supplies used in cardiac monitoring and treatment.
Today's Snapshot
KMTS closed 6.1% lower at 24.07, while its sector was flat. KMTS is due to report earnings on 14 September.
Trading Volume
Above 10d avg 249.9K
302.1K
vs S&P 500 Today
Strong Underperformance
-5.68%
Updated: September 9, 2026 at 20:18 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$24.18 - $25.78Sell
- RSI (14)38.62Neutral
- Stochastic %K (14, 3, 3)13.64Buy
- MACD Level (12, 26)-0.11Sell
Peers & Related Assets
Get premium market insights delivered directly to your inbox.